Adalvo is commencing studies for its generic Letermovir tablets. It’s a significant milestone in bringing a generic version of this complex, first-in-class antiviral to market.
Letermovir is indicated for the prevention of cytomegalovirus (CMV) infection and disease in adults undergoing Hematopoietic Stem Cell Transplants (HSCT) or kidney transplants.
To discuss licensing opportunities, or to see our full range of antiviral therapies, contact one of the team today.
Unlike older antivirals created to treat an active infection, Letermovir prevents CMV from becoming active in the first place by targeting the viral terminase complex, an enzyme unique to CMV that is not found in human cells.
This ensures the virus stays dormant, and means Letermovir avoids the bone marrow toxicity (neutropenia) and kidney toxicity (nephrotoxicity) associated with older antivirals.
According to IQVIA, global sales of Letermovir reached $1.1 billion in the last year.
With strong in-house capabilities and an extensive global supplier network, Adalvo is well positioned to overcome the technical and API sourcing challenges of this high-barrier molecule, and offer Day-1 opportunities for partners.
To discuss licensing opportunities or to see our full portfolio of antiviral therapies contact us today.